Industry News
Biotechnology Industry News
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach
Mirati, Sanofi join forces in lung cancer with a KRAS-SHP2 combo approach badams Fri, 10/08/2021 - 03:58
FDA stops all Allogene’s CAR-T trials over safety scare, raising questions about future of gene editing
FDA stops all Allogene's CAR-T trials over safety scare, raising questions about future of gene editing ntaylor Fri, 10/08/2021 - 03:48
Bristol Myers Squibb’s deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster ntaylor Thu, 10/07/2021 - 08:09
Denali makes ALS play, hustling Sanofi-partnered drug into phase 2 and sharing early data on internal program
Denali makes ALS play, hustling Sanofi-partnered drug into phase 2 and sharing early data on internal program ntaylor Thu, 10/07/2021 - 04:33
Meet Neumora, Arch’s $500M, Amgen-partnered play for the targeted future of neuroscience R&D
Meet Neumora, Arch's $500M, Amgen-partnered play for the targeted future of neuroscience R&D ntaylor Wed, 10/06/2021 - 11:05
Dengue compound backed by J&J shows potency against the virus and all known variants in mice
Dengue compound backed by J&J shows potency against the virus and all known variants in mice arlene.weintraub Wed, 10/06/2021 - 10:21
EQRx’s affordable drug drive leads to Absci discovery pact
EQRx's affordable drug drive leads to Absci discovery pact ntaylor Wed, 10/06/2021 - 08:11
Yale spinout shows how targeting cancer cells’ acidic environment might enhance immunotherapy
Yale spinout shows how targeting cancer cells' acidic environment might enhance immunotherapy aliu Wed, 10/06/2021 - 07:38
Voyager Therapeutics looks to shake off a tough year as it pens Pfizer gene therapy pact worth $630M
Voyager Therapeutics looks to shake off a tough year as it pens Pfizer gene therapy pact worth $630M badams Wed, 10/06/2021 - 05:08
Takeda slams brakes on narcolepsy program, stopping 2 studies early in response to safety signal
Takeda slams brakes on narcolepsy program, stopping 2 studies early in response to safety signal ntaylor Wed, 10/06/2021 - 04:47
Sanofi poaches Gilead cancer exec Fantin to run its oncology research
Sanofi poaches Gilead cancer exec Fantin to run its oncology research badams Wed, 10/06/2021 - 04:45
Gemini axes CSO and 20% of staff to focus on late-phase plans
Gemini axes CSO and 20% of staff to focus on late-phase plans ntaylor Tue, 10/05/2021 - 07:53
Collins, after 12 years at the NIH helm, will exit by year-end
Collins, after 12 years at the NIH helm, will exit by year-end badams Tue, 10/05/2021 - 07:51
AstraZeneca files for FDA green light of COVID-preventing antibody
AstraZeneca files for FDA green light of COVID-preventing antibody ntaylor Tue, 10/05/2021 - 07:17
New insights into the ‘second brain’ in the gut could inspire treatments for intestinal diseases MSU team reports
New insights into the ‘second brain’ in the gut could inspire treatments for intestinal diseases MSU team reports arlene.weintraub Mon, 10/04/2021 - 10:21
Takeda taps Selecta for $1.1B gene therapy research pact
Takeda taps Selecta for $1.1B gene therapy research pact badams Mon, 10/04/2021 - 09:39
Enanta pulls plug on NASH, seeks to offload assets for combos
Enanta pulls plug on NASH, seeks to offload assets for combos ntaylor Mon, 10/04/2021 - 08:29
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race
J&J spends $100M upfront, with $1.2B in biobucks, to join Roche and Regeneron in bispecific blood cancer race ntaylor Mon, 10/04/2021 - 07:50
Amgen reveals midphase eczema data behind its $400M bet
Amgen reveals midphase eczema data behind its $400M bet ntaylor Mon, 10/04/2021 - 05:27
New map of protein interactions offers opportunity to ‘do such damage to cancer,’ scientists say
New map of protein interactions offers opportunity to 'do such damage to cancer,' scientists say arlene.weintraub Fri, 10/01/2021 - 08:34